Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups
Tamoxifen is used worldwide to treat estrogen receptor-positive breast cancer. It is extensively metabolized, and minimum steady-state concentrations of its metabolite endoxifen (CSS,min ENDX) >5.97 ng/mL have been associated with favorable outcome. Endoxifen formation is mediated by the enzyme C...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
18 May 2021
|
| In: |
Cancers
Year: 2021, Jahrgang: 13, Heft: 10, Pages: 1-13 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13102432 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers13102432 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/13/10/2432 
|
| Verfasserangaben: | Anna Mueller-Schoell, Robin Michelet, Lena Klopp-Schulze, Madelé van Dyk, Thomas E. Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus and Charlotte Kloft |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1762547759 | ||
| 003 | DE-627 | ||
| 005 | 20220820013531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210709s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13102432 |2 doi | |
| 035 | |a (DE-627)1762547759 | ||
| 035 | |a (DE-599)KXP1762547759 | ||
| 035 | |a (OCoLC)1341418238 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a McLaughlin, Anna Margarete |d 1993- |e VerfasserIn |0 (DE-588)1236766040 |0 (DE-627)1762548763 |4 aut | |
| 245 | 1 | 0 | |a Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups |c Anna Mueller-Schoell, Robin Michelet, Lena Klopp-Schulze, Madelé van Dyk, Thomas E. Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus and Charlotte Kloft |
| 264 | 1 | |c 18 May 2021 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.07.2021 | ||
| 520 | |a Tamoxifen is used worldwide to treat estrogen receptor-positive breast cancer. It is extensively metabolized, and minimum steady-state concentrations of its metabolite endoxifen (CSS,min ENDX) >5.97 ng/mL have been associated with favorable outcome. Endoxifen formation is mediated by the enzyme CYP2D6, and impaired CYP2D6 function has been associated with lower CSS,min ENDX. In the Women’s Healthy Eating and Living (WHEL) study proposing the target concentration, 20% of patients showed subtarget CSS,min ENDX at tamoxifen standard dosing. CYP2D6 allele frequencies vary largely between populations, and as 87% of the patients in the WHEL study were White, little is known about the risk for subtarget CSS,min ENDX in other populations. Applying pharmacokinetic simulations, this study investigated the risk for subtarget CSS,min ENDX at tamoxifen standard dosing and the need for dose individualization in nine different biogeographical groups with distinct CYP2D6 allele frequencies. The high variability in CYP2D6 allele frequencies amongst the biogeographical groups resulted in an up to three-fold difference in the percentages of patients with subtarget CSS,min ENDX. Based on their CYP2D6 allele frequencies, East Asian breast cancer patients were identified as the population for which personalized, model-informed precision dosing would be most beneficial (28% of patients with subtarget CSS,min ENDX). | ||
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a CYP2D6 | |
| 650 | 4 | |a genotype | |
| 650 | 4 | |a individualized dosing | |
| 650 | 4 | |a model-informed precision dosing | |
| 650 | 4 | |a personalized dosing | |
| 650 | 4 | |a polymorphism | |
| 650 | 4 | |a tamoxifen | |
| 700 | 1 | |a Michelet, Robin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klopp-Schulze, Lena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dyk, Madelé van |e VerfasserIn |0 (DE-588)1264091184 |0 (DE-627)1812528523 |4 aut | |
| 700 | 1 | |a Mürdter, Thomas E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schwab, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Joerger, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huisinga, Wilhelm |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 700 | 1 | |a Kloft, Charlotte |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 10, Artikel-ID 2432, Seite 1-13 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:10 |g elocationid:2432 |g pages:1-13 |g extent:13 |a Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13102432 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/10/2432 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210709 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |d 50000 |e 910000PM110903137 |e 910100PM110903137 |e 50000PM110903137 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 9 | ||
| 999 | |a KXP-PPN1762547759 |e 3947026684 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups","title":"Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups"}],"person":[{"given":"Anna Margarete","family":"McLaughlin","role":"aut","roleDisplay":"VerfasserIn","display":"McLaughlin, Anna Margarete"},{"family":"Michelet","given":"Robin","roleDisplay":"VerfasserIn","display":"Michelet, Robin","role":"aut"},{"given":"Lena","family":"Klopp-Schulze","role":"aut","roleDisplay":"VerfasserIn","display":"Klopp-Schulze, Lena"},{"roleDisplay":"VerfasserIn","display":"Dyk, Madelé van","role":"aut","family":"Dyk","given":"Madelé van"},{"family":"Mürdter","given":"Thomas E.","roleDisplay":"VerfasserIn","display":"Mürdter, Thomas E.","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Schwab, Matthias","given":"Matthias","family":"Schwab"},{"given":"Markus","family":"Joerger","role":"aut","display":"Joerger, Markus","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Huisinga, Wilhelm","role":"aut","family":"Huisinga","given":"Wilhelm"},{"given":"Gerd","family":"Mikus","role":"aut","roleDisplay":"VerfasserIn","display":"Mikus, Gerd"},{"family":"Kloft","given":"Charlotte","roleDisplay":"VerfasserIn","display":"Kloft, Charlotte","role":"aut"}],"recId":"1762547759","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 09.07.2021"],"id":{"eki":["1762547759"],"doi":["10.3390/cancers13102432"]},"origin":[{"dateIssuedDisp":"18 May 2021","dateIssuedKey":"2021"}],"name":{"displayForm":["Anna Mueller-Schoell, Robin Michelet, Lena Klopp-Schulze, Madelé van Dyk, Thomas E. Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus and Charlotte Kloft"]},"relHost":[{"part":{"text":"13(2021), 10, Artikel-ID 2432, Seite 1-13","volume":"13","extent":"13","year":"2021","issue":"10","pages":"1-13"},"pubHistory":["1.2009 -"],"language":["eng"],"recId":"614095670","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 27.05.2020"],"disp":"Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groupsCancers","title":[{"title_sort":"Cancers","title":"Cancers"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2072-6694"],"zdb":["2527080-1"],"eki":["614095670"]},"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"2009-","dateIssuedKey":"2009","publisher":"MDPI"}],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]}}],"physDesc":[{"extent":"13 S."}]} | ||
| SRT | |a MCLAUGHLINCOMPUTATIO1820 | ||